Caner Saygin: A testament to the fact that flow MRD is insufficient for making treatment decisions in ALL

Caner Saygin, Assistant Professor of Medicine at University of Chicago, shared a post by NEJM, on X:

“We`ve been waiting for this paper. I think this is a testament to the fact that flow MRD is insufficient for making treatment decisions in ALL. I do wonder if NGS MRD- patients still benefited from blina. At this time, blina should be part of standard consolidation for all Ph- B-ALL cases.”

Quoting NEJM‘s post:

“The addition of blinatumomab to consolidation chemotherapy in adults with B-cell precursor acute lymphoblastic leukemia who had minimal residual disease–negative status after treatment improved overall and relapse-free survival.

‘Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults‘

Authors: Mark R. Litzow, Zhuoxin Sun, Ryan J. Mattison, Elisabeth M. Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt,  Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner,  Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A. Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali R. Bhave, Elad Sharon, Richard F. Little, Harry P. Erba, Richard M. Stone, Selina M. Luger, Charles G. Mullighan, and Martin S. Tallman.”

Source: Caner Saygin/X and NEJM/X